Table 2.
Patient | Response | Characteristics (m1/f2; age (y3)) | Phototype | Histological type | BRAF Status (wt7/mut8) | Checkpoint inhibitor therapy | Number of involved organs | Metastasis | Tumor Response at first CT scan11 |
---|---|---|---|---|---|---|---|---|---|
1 | Responders | f, 35 | n.a.4 | SSM5 | mut | anti-PD19 + anti-CTLA410 | 4 | Soft tissue, Lung, Liver, Spleen | PR |
2 | m, 93 | 2 | SSM | wt | anti-PD1 | 2 | Lymph nodes, Lung | SD* | |
3 | f, 49 | 2 | SSM | mut | anti-PD1 + anti-CTLA4 | 4 | Lung, Liver, Lymph nodes, Brain | PR | |
4 | f, 43 | 3 | SSM | wt | anti-PD1 | 4 | Lung, Lymph nodes, Soft tissue, Brain | PR | |
5 | f, 54 | 2 | SSM | mut | anti-PD1 | 2 | Soft tissue, Lymph nodes | PR | |
6 | m, 48 | n.a. | nodular | wt | anti-PD1 | 3 | Lymph nodes, Soft tissue, Bone | PR | |
7 | m, 57 | 2 | nodular | wt | anti-PD1 | 7 | Soft tissue, Lymph nodes, Kidney, Peritoneum, Lung, Bone, Brain | SD* | |
8 | f, 53 | 2 | nodular | mut | anti-PD1 | 1 | Lung | SD* | |
9 | m, 36 | 2 | nodular | wt | anti-PD1 | 2 | Lung, Lymph nodes | PR | |
10 | m, 75 | n.a. | nodular | wt | anti-PD1 | 1 | Lung | PR | |
11 | m, 69 | 2 | nodular | wt | anti-PD1 | 1 | Soft tissue | PR | |
12 | f, 49 | 2 | nodular | wt | anti-PD1 | 1 | Lung | PR | |
13 | m, 30 | 4 | nodular | mut | anti-PD1 | 1 | Brain | PR | |
14 | m, 65 | 2 | naevoid | mut | anti-PD1 + anti-CTLA4 | 4 | Soft tissue, Lung, Lymph nodes, Brain | PR | |
15 | Non-Responders | m, 79 | 2 | LMM6 | wt | anti-PD1 | 2 | Lymph nodes, Liver | SD* |
16 | f, 52 | 2 | SSM | mut | anti-CTLA4 | 5 | Soft tissue, Lung, Liver, Mesenterium, Brain | PD | |
17 | m, 68 | 2 | SSM | wt | anti-PD1 | 8 | Soft tissue, Lymph nodes, Lung, Suprarenal gland, Liver, Intestinum, Bone, Brain | PD | |
18 | f, 58 | 3 | nodular | mut | anti-PD1 | 1 | Brain | PD | |
19 | m, 85 | 3 | nodular | wt | anti-PD1 | 1 | Brain | PD | |
20 | m, 60 | 3 | nodular | wt | anti-PD1 + anti-CTLA4 | 3 | Lymph nodes, Lung, Liver | PD | |
21 | m, 75 | n.a. | desmoplastic | wt | anti-PD1 | 2 | Lymph nodes, Liver | PD |
* pseudoprogression, 1male, 2female, 3years, 4not applicable, 5superficial spreading melanoma, 6lentigo maligna melanoma, 7wild type, 8V600E mutation, 9anti-programmed-cell-death-protein-1, 10anti-cytotoxic-T-lymphocyte-associated-protein-4, 11CR Complete Remission, PR Partial Remission, SD Stable Disease, PD Progressive Disease